FK
Fresenius Kabi iPSUM S.r.l.
CDMO · Villadose (Rovigo), Italy
Overview
Fresenius Kabi iPSUM was formed in 2008 when Fresenius Kabi acquired the Villadose and Muggio plants, and it makes beta-lactam and peptide APIs. The Villadose site near Venice is Fresenius Kabi's peptide API development and manufacturing centre, using chemo-enzymatic peptide synthesis, and is marketed through the group's contract manufacturing business. It holds active US Type II DMFs for Calcitonin, Degarelix, Glucagon, Icatibant, Liraglutide, Octreotide. No regulator inspection record for the site was confirmed in this review.
Capabilities
- Peptide API manufacturing
- Chemo-enzymatic peptide synthesis
- Contract manufacturing
- Beta-lactam APIs
Quality signals
| GMP evidence | Not found |
|---|---|
| Certificates of analysis | Not found |
| Third-party testing | Not found |
| ISO certification | Not found |
| Makes own product | Yes, in-house production |